[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20083529L - Farmasoytisk aktivt morfolinol - Google Patents

Farmasoytisk aktivt morfolinol

Info

Publication number
NO20083529L
NO20083529L NO20083529A NO20083529A NO20083529L NO 20083529 L NO20083529 L NO 20083529L NO 20083529 A NO20083529 A NO 20083529A NO 20083529 A NO20083529 A NO 20083529A NO 20083529 L NO20083529 L NO 20083529L
Authority
NO
Norway
Prior art keywords
morpholinol
pharmaceutically active
solvates
disease
compound
Prior art date
Application number
NO20083529A
Other languages
English (en)
Inventor
David Lee Musso
Philip Frederick Morgan
John Joseph Partidge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Publication of NO20083529L publication Critical patent/NO20083529L/no
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet forbindelsen (+)-(2S,3S)-2-(3-klorofenyl)-3,5,5-trimetyl-2-morfolinol og farmasøytisk akseptable salter og solvater derav, farmasøytiske sammensetninger som inneholder disse, og det er også beskrevet en fremgangsmåte for behandling av depresjon, oppmerksomhetredusert hyperaktivitetsforstyrrelse (ADHD), fedme, migrene, smerte, seksuell feilfunksjon, Parkinson sykdom, Alzheimers sykdom eller avhengighet av kokain eller nikotin-inneholdende (spesielt tobakk) produkter ved anvendelse av en slik forbindelse, salter, solvater eller sammensetninger.
NO20083529A 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol NO20083529L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (1)

Publication Number Publication Date
NO20083529L true NO20083529L (no) 2000-09-19

Family

ID=26312986

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20003721A NO326878B1 (no) 1998-01-21 2000-07-20 Anvendelse av morfolinol
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20003721A NO326878B1 (no) 1998-01-21 2000-07-20 Anvendelse av morfolinol

Country Status (30)

Country Link
US (2) US6274579B1 (no)
EP (2) EP1047428B1 (no)
JP (1) JP2002501025A (no)
KR (1) KR100568063B1 (no)
CN (2) CN1203858C (no)
AP (1) AP1229A (no)
AT (1) ATE365042T1 (no)
AU (1) AU755536B2 (no)
BR (1) BR9907203A (no)
CA (1) CA2318268A1 (no)
CY (1) CY1106828T1 (no)
DE (1) DE69936335T2 (no)
DK (1) DK1047428T3 (no)
EA (1) EA002410B1 (no)
EE (1) EE04452B1 (no)
ES (1) ES2288012T3 (no)
HR (2) HRP20000494B1 (no)
HU (1) HUP0100900A3 (no)
ID (1) ID26334A (no)
IL (2) IL137346A0 (no)
IS (1) IS2494B (no)
NO (2) NO326878B1 (no)
NZ (3) NZ505809A (no)
PL (1) PL193622B1 (no)
PT (1) PT1047428E (no)
SG (1) SG115489A1 (no)
SK (1) SK10912000A3 (no)
TR (1) TR200002126T2 (no)
WO (1) WO1999037305A1 (no)
YU (1) YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501891A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの医薬用途
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR20110043664A (ko) * 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
AU2003269923A1 (en) * 2002-08-23 2004-03-11 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
WO2005042503A1 (en) * 2003-10-27 2005-05-12 Smithkline Beecham Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
CA2635261A1 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
ES2687095T3 (es) 2010-05-21 2018-10-23 Research Triangle Institute Fenilimorfolinas y análogos de las mismas
ES2546492T3 (es) 2010-05-21 2015-09-24 Research Triangle Institute Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
KR100568063B1 (ko) 2006-04-07
CN1203858C (zh) 2005-06-01
AU2328099A (en) 1999-08-09
KR20010034285A (ko) 2001-04-25
PL342012A1 (en) 2001-05-07
ES2288012T3 (es) 2007-12-16
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
AU755536B2 (en) 2002-12-12
HRP20000494B1 (en) 2009-02-28
IS5568A (is) 2000-07-20
CN1528753A (zh) 2004-09-15
EA200000691A1 (ru) 2001-04-23
CY1106828T1 (el) 2012-05-23
WO1999037305A1 (en) 1999-07-29
NO20003721D0 (no) 2000-07-20
DE69936335T2 (de) 2008-02-28
EP1047428B1 (en) 2007-06-20
PL193622B1 (pl) 2007-02-28
DE69936335D1 (de) 2007-08-02
YU67102A (sh) 2004-12-31
HUP0100900A2 (hu) 2002-05-29
BR9907203A (pt) 2000-10-17
EP1047428A4 (en) 2001-12-19
US6274579B1 (en) 2001-08-14
HRP20000494A2 (en) 2000-12-31
IL161942A0 (en) 2005-11-20
JP2002501025A (ja) 2002-01-15
IL137346A0 (en) 2001-07-24
NZ520349A (en) 2004-02-27
DK1047428T3 (da) 2007-10-08
NZ529316A (en) 2004-05-28
SG115489A1 (en) 2005-10-28
AP1229A (en) 2003-12-04
ID26334A (id) 2000-12-14
EP1829544A1 (en) 2007-09-05
NO326878B1 (no) 2009-03-09
TR200002126T2 (tr) 2000-12-21
ATE365042T1 (de) 2007-07-15
HRP20051024A2 (hr) 2006-04-30
EP1047428A1 (en) 2000-11-02
EA002410B1 (ru) 2002-04-25
CN1255389C (zh) 2006-05-10
US6391875B2 (en) 2002-05-21
PT1047428E (pt) 2007-09-07
AP2000001869A0 (en) 2000-09-30
EE200000438A (et) 2001-12-17
EE04452B1 (et) 2005-04-15
NO20003721L (no) 2000-09-19
SK10912000A3 (sk) 2001-04-09
HUP0100900A3 (en) 2002-08-28
NZ505809A (en) 2002-09-27
CN1294513A (zh) 2001-05-09
US20020019396A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
NO20083529L (no) Farmasoytisk aktivt morfolinol
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
MY153718A (en) Formulation of human antibodies for treating tnf-(?) associated disorders
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
NO941937L (no) Sakarinderivater som inhiberer proteolytiske enzymer
FR06C0032I1 (no)
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO1998058911A3 (en) Prostaglandin agonists
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
SE9603725D0 (sv) New teatment
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
MY117960A (en) A new salt
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
ITRM940322A0 (it) "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione".
AU2002211577A1 (en) Protecting therapeutic compositions from host-mediated inactivation
SE9800905D0 (sv) New therapy in glomerulonephritis
YU46300A (sh) Farmaceutski aktivni morfolinol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application